www.fdanews.com/articles/207031-fda-approves-abbvies-rinvoq-for-ulcerative-colitis
FDA Approves AbbVie’s Rinvoq for Ulcerative Colitis
March 18, 2022
The FDA has expanded its approval for AbbVie’s blockbuster Janus kinase (JAK) inhibitor, Rinvoq (upadacitinib), to include adults with moderate-to-severe ulcerative colitis who have had an inadequate response to tumor necrosis factor blockers.
The approval was supported by positive results from three phase 3 trials that all achieved their primary endpoints of clinical remission.
Other FDA-approved indications for Rinvoq include rheumatoid arthritis, psoriatic arthritis and atopic dermatitis.
The drug earned almost $1.7 billion last year and AbbVie projects that it will bring in more than $7.5 billion in global sales by 2025.